Delray Beach Medical Center Performs First Robotic-Assisted Peripheral Vascular Intervention Using Corindus CorPath® GRX Sys...
February 22 2018 - 6:45AM
Business Wire
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a
leading developer of precision vascular robotics, announced today
the successful completion of the first robotic-assisted peripheral
vascular intervention procedure using the recently FDA-cleared
CorPath GRX System. The procedure was performed by Joseph Ricotta,
M.D., Medical Director of Vascular Surgery and Endovascular
Therapy, Tenet Healthcare, Professor of Surgery, Charles E Schmidt
College of Medicine, FAU. CorPath GRX is the first and only
FDA-cleared medical device to bring robotic-assisted precision to
both percutaneous coronary and percutaneous vascular interventional
procedures.
"I am honored to have performed the first peripheral vascular
procedure with CorPath GRX. GRX enables me to combine enhanced
visualization of the X-ray images with the precision of robotics to
transform the way we perform peripheral vascular procedures and
should ultimately improve patient care," said Dr. Ricotta. "I look
forward to partnering with Corindus to pioneer robotics for
endovascular therapies, providing benefits to both healthcare
professionals and patients."
Peripheral artery disease (PAD) is a disease of blood vessels
outside the heart that commonly affects arteries carrying blood to
the lower extremities. It is estimated that 8.5 million people in
the United States are living with PAD.1
"We are privileged to partner with Dr. Ricotta as the first
physician in the U.S. to perform peripheral vascular interventions
with the CorPath GRX System following FDA clearance for this
indication," said Mark Toland, President and Chief Executive
Officer of Corindus. "The adoption of the CorPath GRX System at
Delray Beach Medical Center emphasizes their continuous commitment
to delivering state of the art technology to their patients and
clinical community."
About Corindus Vascular Robotics
Corindus Vascular Robotics, Inc. is a global technology leader
in robotic-assisted vascular interventions. The company's CorPath®
System is the first FDA-cleared medical device to bring robotic
precision to percutaneous coronary and percutaneous vascular
procedures. During the procedure, the interventional cardiologist
sits at a radiation-shielded workstation to advance guide
catheters, stents, and guidewires with millimeter-by-millimeter
precision. The workstation allows the physician greater control and
the freedom from wearing heavy lead protective equipment that
causes musculoskeletal injuries. CorPath GRX is the second
generation robotic-assisted PCI technology offering enhancements to
the platform by adding important key upgrades that increase
precision, improve workflow, and extend the capabilities and range
of procedures that can be performed robotically. With the CorPath
System, Corindus Vascular Robotics brings robotic precision to
interventional procedures to help optimize clinical outcomes and
minimize the costs associated with complications of improper stent
placement during manual procedures. Corindus stands behind its
product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow
@CorindusInc.
Forward Looking Statements
Statements made in this release that are not statements of
historical or current facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements may involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, performance or achievements of Corindus to be materially
different from historical results or from any future results or
projections expressed or implied by such forward-looking
statements. Accordingly, readers should not place undue reliance on
any forward looking statements. In addition to statements that
explicitly describe such risks and uncertainties, readers are urged
to consider statements in the conditional or future tenses or that
includes terms such as "believes," "belief," "expects,"
"estimates," "intends," "anticipates" or "plans" to be uncertain
and forward-looking. Forward-looking statements may include
comments as to Corindus’ beliefs and expectations as to future
events and trends affecting its business and are necessarily
subject to uncertainties, many of which are outside Corindus’
control.
Examples of such statements include statements that GRX enables
enhanced visualization of the x-ray images to be combined with the
precision of robotics to transform the way peripheral vascular
procedures are performed and should ultimately improve patient
care.
Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements
are described in the sections titled "Risk Factors" in the
company's filings with the Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, as well as reports on Form 8-K, including,
but not limited to the following: the rate of adoption of our
CorPath System and the rate of use of our cassettes; risks
associated with market acceptance, including pricing and
reimbursement; our ability to enforce our intellectual property
rights; our need for additional funds to support our operations;
our ability to manage expenses and cash flow; factors relating to
engineering, regulatory, manufacturing, sales and customer service
challenges; potential safety and regulatory issues that could slow
or suspend our sales; and the effect of credit, financial and
economic conditions on capital spending by our potential customers.
Forward looking statements speak only as of the date they are made.
Corindus undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise that occur after that date. More
information is available on Corindus' website at
http://www.corindus.com.
______________________
1 cdc.gov/PAD.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180222005043/en/
Corindus Vascular Robotics, Inc.Media:Kate Stanton,
508-653-3335 ext.
200kate.stanton@corindus.comorInvestor:Lynn Pieper Lewis,
415-937-5402ir@corindus.com
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
From Sep 2023 to Sep 2024